SELLAS Life Sciences GroupSLS -1.28%25 EV-to-EBIT is -81.50 as of Jul. 09, 2026. GuruFocus rates SLS with a GF Score™ of 25/100. The stock has 1 warning sign investors should review. Among 366 Biotechnology companies, SELLAS Life Sciences Group ranks worse than 273223.77% on this metric.
SELLAS Life Sciences Group (NAS:SLS) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
SELLAS Life Sciences Group's Enterprise Value for the quarter that ended in Mar. 2026 was $660.81 Mil.
SELLAS Life Sciences Group's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-31.46 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SELLAS Life Sciences Group EV-to-EBIT Related Terms
SELLAS Life Sciences Group EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, SELLAS Life Sciences Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SELLAS Life Sciences Group EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SELLAS Life Sciences Group's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where SELLAS Life Sciences Group's EV-to-EBIT falls into.
SELLAS Life Sciences Group's current Enterprise Value is $2,564.30 Mil.
SELLAS Life Sciences Group's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-31.46 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SELLAS Life Sciences Group (SLS) has a EV-to-EBIT of -81.50 as of Jul. 09, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on SELLAS Life Sciences Group and its competitors. According to the industry distribution chart, SELLAS Life Sciences Group ranks #999999 out of 366 companies in the Biotechnology industry.
Is SELLAS Life Sciences Group's EV-to-EBIT too high?
SELLAS Life Sciences Group's current EV-to-EBIT is -81.50. Based on the distribution chart, SELLAS Life Sciences Group ranks #999999 out of 366 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, SELLAS Life Sciences Group has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does SELLAS Life Sciences Group's EV-to-EBIT compare to MBX and BHVN?
According to the Biotechnology industry distribution chart, SELLAS Life Sciences Group ranks #999999 out of 366 companies for EV-to-EBIT. This places SELLAS Life Sciences Group in the lower half of its industry. The industry median EV-to-EBIT is 14.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 14.63, based on 366 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on SELLAS Life Sciences Group and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 14.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SELLAS Life Sciences Group's current EV-to-EBIT is -81.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SELLAS Life Sciences Group stock overvalued right now?
SELLAS Life Sciences Group (SLS) has a current EV-to-EBIT of -81.50. The current EV-to-EBIT is -81.50. SELLAS Life Sciences Group's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For SELLAS Life Sciences Group (SLS), the current EV-to-EBIT is -81.50 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
25GF Score
Get the complete analysis for SLS
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLS has been successfully added to your 
